Extending natalizumab up to 8 weeks shown safe and effective in patients with MS, report says
Monday, April 20, 2015 - 15:00
in Health & Medicine
Extending the dose of natalizumab from four weeks up to eight weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy, researchers report.